Anti pseudomonas aeruginosa immune globulin - Immunsystem
Alternative Names: Anti-pseudomonas aeruginosa gamma-globulin; Anti-pseudomonas aeruginosa IgY; Anti-Pseudomonas aeruginosa immunoglobulin Y; Anti-pseudomonas IgY; IgY; Pseudomonas aeruginosa immune globulinLatest Information Update: 24 Dec 2019
At a glance
- Originator IMMUNSYSTEM
- Class Antibacterials; Immunotherapies; Polyclonal antibodies
- Mechanism of Action Cell movement inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cystic fibrosis-associated respiratory tract infections
Most Recent Events
- 24 Dec 2019 Discontinued - Phase-I/II for Cystic fibrosis-associated respiratory tract infections (Prevention) in Sweden (Buccal) (Immunsystem website, December 2019)
- 21 Sep 2015 Phase-I/II development for Cystic fibrosis-associated respiratory tract infections (Prevention) is ongoing in Sweden (NCT00633191)
- 01 Dec 2012 IMMUNSYSTEM completes its phase I/II trial for Cystic fibrosis-associated respiratory tract infections (Prevention) in Sweden (NCT00633191)